Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMP-986 in Overactive Bladder Syndrome
NCT00409539Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of Afacifenacin in overactive bladder syndrome (OAB), sponsored by Sumitomo Pharma America. Started Dec 2006; status: completed.
02
Drugs
Afacifenacin
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT00409539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00409539.